First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval
Author:
- 15 February 2019
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (4) , 1133-1135
Abstract
In August 2017, the FDA took historic action in granting the first approval of gene therapy to tisagenlecleucel. This landmark step brought CAR T-cell therapy to the commercial space and heralded a new era in managing refractory B-cell malignancies and FDA oversight of gene-modified therapies. See related article by O'Leary et al., p. 1142Keywords
Funding Information
- American Society of Hematology (N/A)
- Lymphoma Research Foundation (N/A)
- National Center for Advancing Translational Sciences (UL1TR00457)
This publication has 5 references indexed in Scilit:
- FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic LeukemiaClinical Cancer Research, 2019
- The Next Phase of Human Gene-Therapy OversightNew England Journal of Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2016
- Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T CellsBlood, 2014